Year: 2022

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Topline proof-of-concept data in vitiligo patients expected in 1H 2023BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc....

Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company...

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable...

Study finds proteomic risk scores for cardiovascular disease from SomaSignal® Cardio DM™ tests could support physicians in managing patient outcomes

BOULDER, Colo., Nov. 17, 2022 (GLOBE NEWSWIRE) -- In an upcoming randomized, controlled study enrolling 248 physicians, researchers are measuring...

Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million Series A to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform

-Integration of technologies across proteomics, genetics, structural biology, chemistry, and bioinformatics enables advanced insights into disease biology for accelerated drug...

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in...

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participationTransplantation of islets into...

error: Content is protected !!